Generic drugs account for 90% of U.S. prescriptions yet only 17.5% of total drug spending. That math is possible because […]

The gap between developing a generic drug and a biosimilar is not regulatory paperwork. It is the difference between a

Why the Patent Cliff Is the Pharmaceutical Industry’s Most Predictable Crisis — and the Generic Industry’s Biggest Opportunity Every dollar

When Paragraph IV filings hit the docket, they set off a chain of financial events most analysts only half-understand. Here

Every pharmaceutical analyst knows when the compound patent expires. It is on the Bloomberg terminal, in the 10-K, in every

The average branded drug reaches pharmacy shelves with roughly 10 to 12 years of effective patent life remaining. The average

The $200 billion patent cliff bearing down on Big Pharma through 2030 is not primarily a manufacturing or regulatory problem.

The patent cliff is not a metaphor. When Humira’s U.S. composition-of-matter patent finally cracked open in 2023, AbbVie had already

A single composition-of-matter patent can represent $40 billion in franchise value. At the Patent Trial and Appeal Board (PTAB), that